

SPRINGER NATURE [ ]  
Reference

Vijai Singh  
*Editor*

# Handbook of Synthetic Biology

 Springer

---

# Handbook of Synthetic Biology

---


Vijai Singh  
Editor

# Handbook of Synthetic Biology

With 128 Figures and 76 Tables

 Springer

*Editor*

Vijai Singh 

Department of Biosciences, School of Science

Indrashil University

Rajpur, Mehsana, Gujarat, India

ISBN 978-981-95-3956-7

ISBN 978-981-95-3957-4 (eBook)

<https://doi.org/10.1007/978-981-95-3957-4>

© Springer Nature Singapore Pte Ltd. 2026

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

If disposing of this product, please recycle the paper.

*In loving memory of my beloved grandfather,  
Late Mandal Singh—your wisdom, kindness,  
and blessings continue to illuminate my path  
every day.*

---

## Preface

The *Handbook of Synthetic Biology* serves as a comprehensive reference book, providing a complete and coherent overview of all major facets of synthetic biology. This is a rapidly growing field that employs the application of engineering principles into biology. The recent advancements in synthetic biology have enabled the creation of a number of synthetic designs and complex genetic circuits with a wide range of applications in disease diagnostics and therapy, as well as in the production of biomaterials, biofuels, fine chemicals, and the redesign of existing genetic networks. There is a growing need to design and build next-generation synthetic devices and circuits or technologies capable of addressing critical challenges in healthcare, environmental sustainability, and energy. Synthetic biology facilitates precise genetic manipulation, enhancement, or establishment of a novel function through the use of genetic components including promoter, ribosome binding sites, gene, transcription terminator, and small RNAs—across various organisms and cell types.

This handbook of synthetic biology encompasses several key aspects of synthetic biology, presented in a clear and accessible manner. The handbook is organized into five main sections. **Section I** focuses on the fundamental of synthetic biology; **Section II** highlights recent advances; **Section III** explores several applications; **Section IV** discusses the role of synthetic biology addressing human disease; and **Section V** examines ethical considerations and regulatory framework. Each section follows a consistent structure, providing readers with a comprehensive understanding of the field—from its historical background and foundational principles to the latest methods, technologies, and real-world applications.

This handbook of synthetic biology serves as a valuable resource for researchers, students, scientists, clinicians, stakeholders, policymakers, and practitioners, helping to comprehend the principles of synthetic biology and apply its concept across various levels. We believe that this is the first comprehensive handbook of synthetic biology that encompasses an extensive range of topics in this field. This handbook, presented in a clear and accessible format, offers an informative and engaging overview of synthetic biology, a rich literary text of excellent depth, clarity, and thorough coverage. It provides a strong

foundation—from vital understanding to practical applications—aimed at supporting, growing, and accelerating research and innovation in synthetic biology.

Rajpur, Mehsana, India  
April 2026

Vijai Singh

**Acknowledgments** I am truly delighted to express my heartfelt thanks to all the contributing authors for their excellent contributions to this book. I would also like to extend my sincere appreciation to all reviewers, whose valuable feedback greatly helped shape the quality and enhancement of this handbook. I would like to give thanks to Dr. Soumya Basu (Associate Editor—Clinical Medicine, Biomedicine, and Life Science), Sivadharshini Anandanarayana (Production Editor), and the entire team for their excellent support and seamless management throughout this project.

My sincere appreciation goes to Prof. Rakesh Rawal, Prof. Sudhir P. Singh, Prof. Bharat Maitreya, Dr. Poonam Bhargava, Dr. Ravindra P Singh, Prof. Bhabatosh Das, Dr. Indra Mani, Dr. Pablo Carbonell, Dr. Satya Prakash, Prof. Suresh Ramakrishna, Dr. Dinh-Toi Chu, Prof. Antonia Sagona, Dr. Rodrigo Amaro, and all others—named or unnamed—whose direct or indirect contributions have played a key role for shaping this book.

I am deeply thankful to my Ph.D. students—Khushal Khambhati, Karan Murjani, Khushbu Panchal, and Dharmisha Solanki—whose thoughtful discussion and valuable feedback have helped to shape this book. I also extend my sincere thanks to the leadership, faculty, and staff of Indrashil University for fostering a supportive and inspiring academic environment.

I wish to express my deepest gratitude to my beloved wife Pritee Singh, for her endless, unwavering support, patience, and constant encouragement. My warmest love to my children, Aaradhya and Ayush, who missed my presence during the preparation of this book.

Despite our best efforts, there may be some error that may have inadvertently made its way into this first edition. I welcome feedback from readers that can be useful to improve in future editions. Finally, I offer my heartfelt thanks to God for his supreme grace, which enables me to complete this journey with joy and fulfillment in the form of this book.

Vijai Singh

---

# Contents

## Volume 1

<b>Section I Fundamentals of Synthetic Biology</b> . . . . .	1
<b>1 Overview of Synthetic Biology</b> . . . . .	3
Khushal Khambhati, Khushbu Panchal, and Vijai Singh	
<b>2 Computational Tools in Synthetic Biology</b> . . . . .	33
Nhat Le Bui, Minh Son Le, Thanh-Duyen Tran Thi, and Dinh-Toi Chu	
<b>3 Design and Characterization of Genetic Parts in Synthetic Biology</b> . . . . .	55
Ali Samy Abdelaal and Fernando G. Sorroche	
<b>4 Standardization and Modularity in Synthetic Biology</b> . . . . .	85
Juveriya Israr and Ajay Kumar	
<b>5 Design and Implementation of Synthetic Oscillators</b> . . . . .	115
Boris Kirov and Slavil Peykov	
<b>6 Biologic Gates and Their Applications</b> . . . . .	145
Yukti Singh, Saumya Agrawal, Sandhya Mehrotra, and Rajesh Mehrotra	
<b>7 Synthetic Networks</b> . . . . .	177
Gholamreza Abdi, Kirtan Dave, Unnati Panchal, and Saloni Gautam	
<b>8 Design and Applications of Riboregulators</b> . . . . .	203
Dimitrios Kaloudas, Martina Traykovska, Nikolet Pavlova, and Robert Penchovsky	
<b>9 Design and Applications of Riboswitches</b> . . . . .	245
Rugvedi P. Kadu, Krushna Shinde, and Ambadas B. Rode	

---

<b>Section II</b>	<b>Advances in Synthetic Biology</b>	<b>275</b>
<b>10</b>	<b>Design and Characterization of the Synthetic Microbial Genome</b>	<b>277</b>
	Nomthandazo Twala, Mutsa M. Takundwa, Earl Prinsloo, and Deepak B. Thimiri Govinda Raj	
<b>11</b>	<b>Expansion of Genetic Codes and Its Applications</b>	<b>301</b>
	Kowsalya Arjun Balakrishna, Karthik Loganathan, and Sai Ramesh Anjaneyulu	
<b>12</b>	<b>Xenonucleic Acids and Their Applications</b>	<b>317</b>
	Gholamreza Abdi, Kirtan Dave, Saloni Gautam, and Unnati Panchal	
<b>13</b>	<b>Minimal Cells</b>	<b>341</b>
	Karan Murjani and Vijai Singh	
<b>14</b>	<b>Synthetic Cells</b>	<b>357</b>
	Paola Albanese, Roberto Barbaro, Fabio Mavelli, and Emiliano Altamura	
<b>15</b>	<b>Cell-Free Systems</b>	<b>387</b>
	Kavita Yadav, Vikash Kumar Yadav, Nadanai Laohakunakorn, and Bhanvi Kumawat	
<b>16</b>	<b>Gene and Genome Assembly</b>	<b>417</b>
	Slavil Peykov and Boris Kirov	
<b>17</b>	<b>De Novo Gene Synthesis</b>	<b>453</b>
	Satyendra Singh, Kirti Baghel, and Vijay Kumar Prajapati	
<b>18</b>	<b>Protein Engineering and Directed Evolution</b>	<b>475</b>
	Erin Elsa Abey, Anjana Eettikkal Mathew, Aysha Hiba Sheikhinte Veettil, and Vishnu Kirthi Arivarasan	
<b>19</b>	<b>Genome Reduction and Its Applications</b>	<b>515</b>
	Sathya Narayanan Venkatesan, Sujay Patil, Sangamithra Senthilkumar, and Mugesh Sankaranarayanan	
<b>20</b>	<b>Self-Assembled Biomaterials</b>	<b>543</b>
	Muhammad Saqlain Mushtaq, Muhammad Saad Latif, Fahad Ali Noori, and Mustafeez Mujtaba Babar	
<b>21</b>	<b>CRISPR-Cas Systems</b>	<b>567</b>
	Rongming Liu, Cheng Yu, Peiyao Cao, Hongle Wang, and Liya Liang	

---

**Volume 2**

<b>Section III Applications of Synthetic Biology</b> . . . . .	601
<b>22 Synthetic Biology-Based Diagnostic Tools</b> . . . . .	603
Gaurang Agarwal, Lalit Sharma, and Anupam Jyoti	
<b>23 Synthetic Biology-Based Biosensors</b> . . . . .	629
Dharmisha Solanki, Karan Murjani, and Vijai Singh	
<b>24 RNA-Based Therapeutics</b> . . . . .	649
Aneela Mustafa, Tayaba Irfan, Mustafeez Mujtaba Babar, and Jayakumar Rajadas	
<b>25 RNA-Based Vaccines</b> . . . . .	675
Hajra Ali Raja, Fatima Noor Malik, Hunaiza Fatima, and Mustafeez Mujtaba Babar	
<b>26 Cell-Based Therapy</b> . . . . .	697
Hue Vu Thi, My-Hanh Do Thi, Van Anh Pham Thi, Anh Dao Ngo, and Dinh-Toi Chu	
<b>27 Synthetic Biology for Cancer Stem Cells</b> . . . . .	715
Arpita Poddar, Suresh Ramakrishna, Ravi Shukla, Haiyan Li, Prashanth Prithviraj, George Kannourakis, and Aparna Jayachandran	
<b>28 Synthetic Biology for Drug Discovery</b> . . . . .	745
Nisheeth Agarwal, Himanshu Gogoi, E. Eeba, and Linus Augustin	
<b>29 Synthetic Biology for Drug Repurposing</b> . . . . .	783
Ehtisham Ul Haq, Muneeb Ahmad Khan, Kinza Mujahid, and Mustafeez Mujtaba Babar	
<b>30 Synthetic Biology in Human Microbiome</b> . . . . .	817
Ingita Dey Munshi, Mansi Acharya, and Indra Mani	
<b>31 Synthetic Biology for Deciphering Cancer Mechanisms</b> . . . . .	843
Gayatri Shamsunder Salgaonkar, Dishita Dutta, Vinayak Shishodia, and Dhruv Kumar	
<b>32 Synthetic Circuits for the Detection of Bacteria</b> . . . . .	859
Monisa Anwer and Ajay Kumar	
<b>33 Synthetic Circuits for the Detection of Viruses</b> . . . . .	879
Dharmisha Solanki and Vijai Singh	
<b>34 Synthetic Phage for the Detection of Bacteria</b> . . . . .	895
Anuj Yadav and Ajay Kumar	

---

<b>35</b>	<b>Synthetic Phage for the Detection of Cancer</b> .....	923
	Gauri Gaur, Ayush Seth, Palak Jain, and Dhruv Kumar	
<b>36</b>	<b>Synthetic Phage for the Evolution of Biomolecules</b> .....	949
	Gholamreza Abdi, Kirtan Dave, and Saloni Gautam	
<b>37</b>	<b>Synthetic Biology in Precision Medicine and Nanotechnology</b> .....	973
	Aparna Jayachandran, Suresh Ramakrishna, Ravi Shukla, Prashanth Prithviraj, George Kannourakis, and Arpita Poddar	
	<b>Section IV Synthetic Biology for Human Disease</b> .....	999
<b>38</b>	<b>Design of Chimeric Antigen Receptor (CAR) T Cell Therapy</b> .....	1001
	María Tristán-Manzano, Jon Ruiz de Francisco, Ana Hinckley-Boned, and Francisco Martin	
<b>39</b>	<b>Synthetic Biology for Treatment of Cancer</b> .....	1041
	Huzaifa Ibrahim, Shah Fawad, Hafsa Adnan, and Jayakumar Rajadas	
<b>40</b>	<b>Synthetic Biology for Treatment of Blood Disorders</b> .....	1061
	Ingita Dey Munshi, Ruchika Riya Tirkey, and Indra Mani	
<b>41</b>	<b>Synthetic Biology for Treatment of Metabolic Disorders</b> .....	1083
	Santhosh Kumar Yasam, Joice Kuzhipalayil Joseph, and Senthilkumar Rajagopal	
<b>42</b>	<b>Synthetic Biology for Treatment of Neurological Diseases</b> .....	1113
	Jyoti Singh, Aditi Sharma, Anupam Jyoti, and Lalit Sharma	
<b>43</b>	<b>Synthetic Biology for Diagnosis and Therapy of Genetic Disorders</b> .....	1141
	Devangi Zala, Shuvomoy Banerjee, Ansh Mehta, and Anand K. Tiwari	
	<b>Section V Synthetic Biology Ethics and Regulations</b> .....	1171
<b>44</b>	<b>Synthetic Biology for Biosafety and Ethics</b> .....	1173
	Prachi Nawkarkar and Shashi Kumar	
<b>45</b>	<b>Synthetic Biology Patents and Technology</b> .....	1193
	Ila Mukul Tiwari, Bhavna Badgotya, Jayshree Pawar, and Kanti Kiran	
<b>46</b>	<b>Impact of Synthetic Biology on Society</b> .....	1213
	Ingita Dey Munshi, Mansi Acharya, and Indra Mani	

---

<b>47 Synthetic Biology Regulatory Landscape</b> .....	1237
Abhinav Warriar, Rashi Diwan, Gayatri D. Lele, Srushti N. Tijare, Tanvi R. Sonawane, and Shamlan M. S. Reshamwala	
<b>48 Economic Aspects of Synthetic Biology</b> .....	1263
Hue Vu Thi, Minh-Hanh Nguyen, Mai-Trang Ngo, and Dinh-Toi Chu	
<b>Index</b> .....	1277

---

## About the Editor



**Dr. Vijai Singh** is a Professor and Head of the Department of Biosciences, School of Science, and Dean (Research & Innovation) at Indrashil University, Rajpur, Mehsana, India. He served as an Associate Professor in the Department of Biosciences at the same university. Earlier, he worked as an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, and in the Department of Biotechnology at Invertis University, Bareilly, India. Prior to that, he was a Post-doctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France, and the School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He earned his Ph.D. in Biotechnology (2009) from the ICAR–National Bureau of Fish Genetic Resources and Uttar Pradesh Technical University, Lucknow, India, where his research focused on developing molecular and immunoassays for the diagnosis of *Aeromonas hydrophila*.

His research interests are focused on design of a novel biosynthetic pathway for production of medically and industrially important biomolecules. His laboratory is actively working on CRISPR-Cas9-based genome editing tools and has developed CRISPR-based diagnostics for *Klebsiella pneumoniae*. His laboratory is strongly supported by national and state government funding agencies to drive research and innovations. With over 15 years of experience in research and teaching, his areas of specialization include synthetic biology, genome editing, metabolic engineering, and industrial microbiology. He has authored 244 Scopus-indexed publications, including 111 research articles, 30 books, and 91 book chapters, and holds 3 patents. He has

received several prestigious awards, including the Bioclues Innovation, Research and Development Award (2023) by the BIOCLUES Society, the Vice Chancellor's Best Research Award (2023) by Indrashil University, and the Agathiyar Chemical Biology Award (2023) by the Society of Chemical and Synthetic Biology. He serves as associate editor, editorial board member, and reviewer for peer-reviewed international journals.

---

## Contributors

**Ali Samy Abdelaal** Department of Agricultural Biotechnology, Faculty of Agriculture, Damietta University, New Damietta, Egypt

Bio & Chemical Engineering, Toulouse Biotechnology Institute, INSA, University of Toulouse, Toulouse, France

**Gholamreza Abdi** Department of Biotechnology, Persian Gulf Research Institute, Persian Gulf University, Bushehr, Iran

**Erin Elsa Abey** Department of Microbiology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India

**Mansi Acharya** School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India

**Hafsa Adnan** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Gaurang Agarwal** Inflammation Research Laboratory, Department of Life Science, Parul Institute of Applied Science, Parul University, Vadodara, Gujarat, India

**Nisheeth Agarwal** Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India

**Saumya Agrawal** Department of Biological Sciences, BITS-Pilani, Pilani, India

**Paola Albanese** Department of Physical Sciences, Earth and Environment, University of Siena, Siena, Italy

Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy

**Emiliano Altamura** Department of Chemistry, University of Bari, Bari, Italy

**Sai Ramesh Anjaneyulu** Department of Bio-Engineering, School of Engineering, Vels Institute of Science, Technology, and Advanced Studies (VISTAS), Chennai, India

**Monisa Anwer** Department of Biotechnology, Faculty of Science and Engineering, Rama University, Kanpur, India

**Vishnu Kirthi Arivarasan** Department of Microbiology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India

**Linus Augustin** Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India

**Mustafeez Mujtaba Babar** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

Advanced Regenerative Biomaterial laboratory, Cardiovascular Institute, School of Medicine, Stanford University, Palo Alto, CA, USA

**Bhavna Badgotya** Gujarat Biotechnology University, Gandhinagar, India

**Kirti Baghel** Department of Biochemistry, University of Delhi South Campus, Dhaula Kuan, New Delhi, India

**Kowsalya Arjun Balakrishna** Anna University, Chennai, Tamil Nadu, India

**Shuvomoy Banerjee** Biochemistry Laboratory, School of Biotechnology & Bioengineering, Institute of Advanced Research, Gandhinagar, Gujarat, India

**Roberto Barbaro** Department of Chemistry, University of Bari, Bari, Italy

**Peiyao Cao** MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian, University of Technology, Dalian, China

**Dinh-Toi Chu** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

Faculty of Applied Sciences, International School, Vietnam National University, Hanoi, Vietnam

**Kirtan Dave** Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat, India

Bioinformatics Laboratory, Research & Development Cell, Parul University, Vadodara, Gujarat, India

**Jon Ruiz de Francisco** LentiStem Biotech, Granada, Spain

**Rashi Diwan** Department of Economics, Kalindi College, Delhi University, New Delhi, India

**My-Hanh Do Thi** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

**Dishita Dutta** School of Health Sciences and Technology (SoHST), UPES, Dehradun, India

**E. Eeba** Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India

**Hunaiza Fatima** Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan

**Shah Fawad** Atta-Ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan

**Gauri Gaur** School of Health Sciences and Technology (SoHST), UPES, Dehradun, India

**Saloni Gautam** Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat, India

Bioinformatics Laboratory, Research & Development Cell, Parul University, Vadodara, Gujarat, India

**Himanshu Gogoi** Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India

**Ehtisham Ul Haq** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Ana Hinckley-Boned** GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Spain

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain

**Huzaiifa Ibrahim** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Tayaba Irfan** Atta-Ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan

**Juveriya Israr** Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Barabanki, Uttar Pradesh, India

Department of Biotechnology, Era University, Lucknow, Uttar Pradesh, India

**Palak Jain** School of Health Sciences and Technology (SoHST), UPES, Dehradun, India

**Aparna Jayachandran** Fiona Elsey Cancer Research Institute, Ballarat, VIC, Australia

**Joice Kuzhipalayil Joseph** Department of Biotechnology, School of Applied Sciences, REVA University, Bangalore, KA, India

**Anupam Jyoti** Inflammation Research Laboratory, Department of Life Science, Parul Institute of Applied Science, Parul University, Vadodara, Gujarat, India

**Rugvedi P. Kadu** Laboratory of Synthetic Biology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India

**Dimitrios Kaloudas** Laboratory of Synthetic Biology and Bioinformatics, Faculty of Biology, Sofia University “St. Kliment Ohridski”, Sofia, Bulgaria

**George Kannourakis** Fiona Elsey Cancer Research Institute, Ballarat, VIC, Australia

Federation University, Ballarat, VIC, Australia

**Khushal Khambhati** Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India

**Muneeb Ahmad Khan** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Kanti Kiran** Gujarat Biotechnology University, Gandhinagar, India

**Boris Kirov** Department Industrial Automation, Technical University of Sofia, Sofia, Bulgaria

Faculty of German Engineering Education and Industrial Management (FDIBA), Technical University of Sofia, Sofia, Bulgaria

BioInfoTech Laboratory, Sofia Tech Park, Tsarigradsko Shose Blvd, Sofia, Bulgaria

**Ajay Kumar** Department of Biotechnology, Faculty of Engineering and Technology (FET), Rama University, Kanpur, UP, India

**Dhruv Kumar** School of Health Sciences and Technology (SoHST), UPES, Dehradun, India

**Shashi Kumar** Metabolic Engineering Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India

**Bhanvi Kumawat** Synthetic Biology and Biomanufacturing Laboratory, Department of Industrial Biotechnology, Gujarat Biotechnology University, Gandhinagar, Gujarat, India

**Nadanai Laohakunakorn** Centre for Engineering Biology, Institute of Quantitative Biology, Biochemistry, and Biotechnology, School of Biological Sciences, University of Edinburgh, Edinburgh, UK

**Muhammad Saad Latif** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Minh Son Le** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

Faculty of Applied Sciences, International School, Vietnam National University, Hanoi, Vietnam

**Nhat Le Bui** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

Faculty of Applied Sciences, International School, Vietnam National University, Hanoi, Vietnam

**Gayatri D. Lele** Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Mumbai, India

**Haiyan Li** RMIT University, Melbourne, VIC, Australia

**Liya Liang** MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian, University of Technology, Dalian, China

**Rongming Liu** MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian, University of Technology, Dalian, China

Ningbo Institute of Dalian University of Technology, Ningbo, China

**Karthik Loganathan** Arqgene, Vellore, Tamil Nadu, India

**Fatima Noor Malik** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Indra Mani** Department of Microbiology, Gargi College, University of Delhi, New Delhi, India

**Francisco Martin** GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Spain

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain

LentiStem Biotech, Granada, Spain

Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, University of Granada, Granada, Spain

**Anjana Eettikkal Mathew** Department of Microbiology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India

**Fabio Mavelli** Department of Chemistry, University of Bari, Bari, Italy

**Rajesh Mehrotra** Department of Biological Sciences, BITS-Pilani, Pilani, India

**Sandhya Mehrotra** Department of Biological Sciences, BITS-Pilani, Pilani, India

**Ansh Mehta** Genetics & Developmental Biology Laboratory, School of Biotechnology & Bioengineering, Institute of Advanced Research, Gandhinagar, Gujarat, India

**Kinza Mujahid** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Ingita Dey Munshi** School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India

**Karan Murjani** Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India

**Muhammad Saqlain Mushtaq** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Aneela Mustafa** Atta-Ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan

**Prachi Nawkarkar** Metabolic Engineering Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India

**Anh Dao Ngo** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

**Mai-Trang Ngo** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

**Minh-Hanh Nguyen** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

**Fahad Ali Noori** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

**Khushbu Panchal** Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India

**Unnati Panchal** Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat, India

Bioinformatics Laboratory, Research & Development Cell, Parul University, Vadodara, Gujarat, India

**Sujay Patil** Department of Biotechnology, Dayanand Science College, Latur, Maharashtra, India

**Nikolet Pavlova** Laboratory of Synthetic Biology and Bioinformatics, Faculty of Biology, Sofia University “St. Kliment Ohridski”, Sofia, Bulgaria

**Jayshree Pawar** Gujarat Biotechnology University, Gandhinagar, India

**Robert Penchovsky** Laboratory of Synthetic Biology and Bioinformatics, Faculty of Biology, Sofia University “St. Kliment Ohridski”, Sofia, Bulgaria

**Slavil Peykov** BioInfoTech Lab, RDIC at Sofia tech Park, Sofia, Bulgaria

Department of Genetics, Faculty of Biology, SU ‘St. Kliment Ohridski’, Sofia, Bulgaria

**Slavil Peykov** Department of Genetics, Faculty of Biology, University of Sofia “St. Kliment Ohridski”, Sofia, Bulgaria

BioInfoTech Laboratory, Sofia Tech Park, Sofia, Bulgaria

Department of Medical Microbiology “Corr. Mem. Prof. Ivan Mitov, MD, DMSc”, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria

**Arpita Poddar** Fiona Elsey Cancer Research Institute, Ballarat, VIC, Australia  
Federation University, Ballarat, VIC, Australia

RMIT University, Melbourne, VIC, Australia

The University of Melbourne, Parkville, VIC, Australia

**Vijay Kumar Prajapati** Department of Biochemistry, University of Delhi South Campus, Dhaula Kuan, New Delhi, India

**Earl Prinsloo** Biotechnology Innovation Centre, Rhodes University, Makhanda, South Africa

**Prashanth Prithviraj** Fiona Elsey Cancer Research Institute, Ballarat, VIC, Australia

Federation University, Ballarat, VIC, Australia

**Hajra Ali Raja** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

Health Services Academy, Ministry of Health, Islamabad, Pakistan

**Jayakumar Rajadas** Advanced Regenerative Biomaterial laboratory, Cardiovascular Institute, School of Medicine, Stanford University, Palo Alto, CA, USA

**Senthilkumar Rajagopal** Department of Biotechnology, School of Applied Sciences, REVA University, Bangalore, KA, India

Center for Biotechnology and Molecular Biology Laboratory, REVA Research Center, REVA University, Bangalore, KA, India

**Suresh Ramakrishna** Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea

College of Medicine, Hanyang University, Seoul, South Korea

**Shamlan M. S. Reshamwala** Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Mumbai, India

**Ambadas B. Rode** Laboratory of Synthetic Biology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India

**Gayatri Shamsunder Salgaonkar** School of Health Sciences and Technology (SoHST), UPES, Dehradun, India

**Mugesh Sankaranarayanan** Department of Biotechnology, Centre for Metabolic Engineering and Synthetic Biology, Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology, Avadi, Chennai, Tamil Nadu, India

Park's Biolabs LLP, Chennai, India

**Sangamithra Senthilkumar** Department of Biotechnology, Vel Tech High Tech Dr. Rangarajan Dr. Sakunthala Engineering College, Avadi, Chennai, Tamil Nadu, India

**Ayush Seth** School of Health Sciences and Technology (SoHST), UPES, Dehradun, India

**Aditi Sharma** Department of Pharmacology, Faculty of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Bajhol, Solan, Himachal Pradesh, India

**Lalit Sharma** Department of Pharmacology, Faculty of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Bajhol, Solan, Himachal Pradesh, India

**Krushna Shinde** Laboratory of Synthetic Biology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India

**Vinayak Shishodia** School of Health Sciences and Technology (SoHST), UPES, Dehradun, India

**Ravi Shukla** RMIT University, Melbourne, VIC, Australia

**Jyoti Singh** Department of Pharmacology, Faculty of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Bajhol, Solan, Himachal Pradesh, India

**Satyendra Singh** Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Kishangarh/Ajmer, Rajasthan, India

**Vijai Singh** Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India

**Yukti Singh** Department of Biological Sciences, BITS-Pilani, Pilani, India

**Dharmisha Solanki** Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India

**Tanvi R. Sonawane** Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Mumbai, India

**Fernando G. Sorroche** Bio & Chemical Engineering, Toulouse Biotechnology Institute, INSA, University of Toulouse, Toulouse, France

**Mutsa M. Takundwa** Synthetic Nanobiotechnology and Biomachines, Synthetic Biology and Precision Medicine Centre, CSIR, Pretoria, South Africa

Biotechnology Innovation Centre, Rhodes University, Makhanda, South Africa

**Hue Vu Thi** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

Faculty of Applied Sciences, International School, Vietnam National University, Hanoi, Vietnam

**Thanh-Duyen Tran Thi** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

Faculty of Applied Sciences, International School, Vietnam National University, Hanoi, Vietnam

**Van Anh Pham Thi** The Interdisciplinary Research Group on Biomedicine and Health, International School, Vietnam National University, Hanoi, Vietnam

**Deepak B. Thimiri Govinda Raj** Synthetic Nanobiotechnology and Biomachines, Synthetic Biology and Precision Medicine Centre, CSIR, Pretoria, South Africa  
Biotechnology Innovation Centre, Rhodes University, Makhanda, South Africa

**Srushti N. Tijare** Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Mumbai, India

**Ruchika Riya Tirkey** School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India

**Anand K. Tiwari** Genetics & Developmental Biology Laboratory, School of Biotechnology & Bioengineering, Institute of Advanced Research, Gandhinagar, Gujarat, India

**Ila Mukul Tiwari** ICAR-National Institute for Plant Biotechnology, New Delhi, India

**Martina Traykovska** Laboratory of Synthetic Biology and Bioinformatics, Faculty of Biology, Sofia University “St. Kliment Ohridski”, Sofia, Bulgaria

**María Tristán-Manzano** GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Spain

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain

LentiStem Biotech, Granada, Spain

**Nomthandazo Twala** Synthetic Nanobiotechnology and Biomachines, Synthetic Biology and Precision Medicine Centre, CSIR, Pretoria, South Africa  
Biotechnology Innovation Centre, Rhodes University, Makhanda, South Africa

**Aysha Hiba Sheikhinte Veetil** Department of Microbiology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India

**Sathya Narayanan Venkatesan** Department of Biotechnology, Centre for Metabolic Engineering and Synthetic Biology, Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology, Avadi, Chennai, Tamil Nadu, India

**Hongle Wang** MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian, University of Technology, Dalian, China

**Abhinav Warriier** Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India

**Anuj Yadav** Department of Biotechnology, Faculty of Engineering and Technology (FET), Rama University, Kanpur, UP, India

**Kavita Yadav** Synthetic Biology and Biomanufacturing Laboratory, Department of Industrial Biotechnology, Gujarat Biotechnology University, Gandhinagar, Gujarat, India

**Vikash Kumar Yadav** Biomedical and Clinical Sciences, School of Science, University of Derby, Derby, UK

**Santhosh Kumar Yasam** Department of Biotechnology, Karpaga Vinayaga College of Engineering & Technology, GST Road, Maduranthakam, TN, India

**Cheng Yu** MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian, University of Technology, Dalian, China

**Devangi Zala** Genetics & Developmental Biology Laboratory, School of Biotechnology & Bioengineering, Institute of Advanced Research, Gandhinagar, Gujarat, India



# Expansion of Genetic Codes and Its Applications

# 11

Kowsalya Arjun Balakrishna, Karthik Loganathan,  
and Sai Ramesh Anjaneyulu

## Contents

Introduction .....	302
Canonical Genetic Code and Its Limitations .....	303
Structure and Evolution of the Canonical Code .....	303
Chemical Constraints of Natural Amino Acids .....	303
Need and Strategies for Genetic Code Expansion .....	304
Orthogonal tRNA and Aminoacyl-tRNA Synthetase (aaRS) Pairs .....	305
Stop Codon Suppression .....	305
Sense Codon Reassignment .....	306
Quadruplet Codon Expansion .....	306
Incorporation of Noncanonical Amino Acids .....	307
Chemical Diversity and Functional Classes .....	307
Genetic Engineering Tools for <i>ncAA</i> Incorporation .....	307
Advantages of Noncanonical Amino Acids ( <i>ncAAs</i> ) .....	308
Applications of Genetic Code Expansion (GCE) .....	309
Applications of GCE in Protein Engineering .....	310
Applications in Synthetic and Systems Biology .....	311
Challenges and Limitations .....	312
Efficiency and Fidelity of <i>ncAA</i> Incorporation .....	312
Cellular Toxins and Metabolic Burden .....	313
Codon Operations and Genome Recoding Complexity .....	313
Conclusion .....	313
References .....	314

---

K. A. Balakrishna  
Anna University, Chennai, Tamil Nadu, India

K. Loganathan  
Arqgene, Vellore, Tamil Nadu, India

S. R. Anjaneyulu (✉)  
Department of Bio-Engineering, School of Engineering, Vels Institute of Science, Technology,  
and Advanced Studies (VISTAS), Chennai, India

---

**Abstract**

The genetic code has traditionally been viewed as a universal and unchanging aspect of life, specifying 20 standard amino acids via 64 triplet codons. The development in synthetic biology, molecular genetics, and evolutionary engineering has drastically reinterpreted this conception for the extension of the genetic code to include noncanonical amino acids (*ncAAs*) into proteins. Genome editing and synthetic genomics have also contributed to global codon reassignment, which has opened up avenues toward the creation of semisynthetic organisms with expanded inheritable canons. Genetic code expansion (GCE) in protein engineering enables the creation of proteins with significant stability, enzymatic activity, and new list activities. In medicine discovery and chemical biology, *ncAAs* are new biochemical handles for point-specific conjugation, bio-orthogonal labeling, and targeted remedial delivery. The use of GCE in systems biology has enabled the creation of biosynthetic pathways to produce new composites and enabled biocontainment approaches through engineering organisms that are reliant on synthetic amino acids. Though it holds a similar transformative pledge, GCE is still hampered by several limitations such as low objectification effectiveness, cellular toxin of *ncAAs*, competition with the natural restatement outfit, and the intricacy of large-scale codon reassignment. Thus, the current studies try to overcome these scarcities and offers an expansive summary of strategies for GCE and the broad range of its operations to biotechnology, drug, and synthetic biology. This review also includes challenges and investigates unborn perspectives for icing GCE becomes a safe and scalable tool in exploration as well as applied biosciences.

---

**Keywords**

Genetic code expansion · Noncanonical amino acids · Orthogonal systems · Protein engineering · Synthetic biology

---

**Introduction**

The universal genetic code is made up of 64 triplet codons and canons for 20 universal amino acids and restatement stop signals. Long considered to be a universal and unchanging language of life, the genetic code was traditionally held to be an evolutionary optimized, conserved result (Crick 1968; Osawa et al. 1992). Recent advances in synthetic biology and molecular engineering have demonstrated that the codon is more evolvable and flexible (Knight et al. 2001). The genetic code expansion (GCE) utilizes finagled orthogonal restatement ministry, similar to functionally independent tRNA/aminoacyl-tRNA synthetase dyads, to introduce point-specific *ncAA* objectification via stop codon repression, sense codon reassignment, and quadruplet codon operation (Kryukov et al. 2003). Also, GCE allows the addition of noncanonical amino acids (*ncAAs*) to proteins with new chemical, physical, and natural activities (Mehl et al. 2003; Furter 1998). The driving force behind GCE comes from the

necessity to overcome the chemical limitations of the natural amino acid set. By introducing synthetic or altered amino acids, scientists are able to design proteins with increased structural delicacy, target-point particularity, and catalytic performance (Blight et al. 2004). Similar developments have profound benefits in structural biology, biopharmaceuticals, diagnostics, and biocontainment (Hao et al. 2002; Johansson et al. 2005; Rayman 2000).

This review offers a detailed overview of GCE methodologies and the bioengineering ways that make this technology revolution possible. It also discusses the general operations of GCE in protein wisdom, systems biology, and remedial development, with a final discussion on current challenges and implicit directions for future exploration.

---

## Canonical Genetic Code and Its Limitations

### Structure and Evolution of the Canonical Code

The universal genetic code is nearly the same in all known forms of life and consists of 64 codons—61 sense codons that decode for amino acids and 3 stop codons that mark the end of restatement (Crick 1966; Osawa et al. 1992). The descent of the codon, in which more than one codon can decode for the same amino acid, protects against dangerous mutations and translational stability (Crick 1966; Knight et al. 2001). For example, leucine has six different codons that decode for it, whereas methionine and tryptophan each have a unique codon (Crick 1968). It's taken for granted that the genetic code evolved under optimization of error minimization and translational effectiveness constraints (Kisselev et al. 2003). The coevolution proposition proposes that codon assignments coevolved with amino acid biosynthesis pathways (Osawa et al. 1992), whereas the stereochemical proposition proposes direct relations between amino acids and codons (Agris 2004). Nonetheless, even with this optimization through elaboration, the genetic code is bound by its limited chemical functionality force (Knight et al. 2001).

These constraints become indeed clear in synthetic and systems biology, in which there's a demand for increased biochemical diversity (Mehl et al. 2003; Furter 1998). The standard amino acids, although acceptable for the maturity of natural functions, are lacking in enabling sophisticated molecular design, particularly for operations involving new reactivity, specific list, or light-responsive behavior (Blight et al. 2004; Polycarpo et al. 2004).

### Chemical Constraints of Natural Amino Acids

The 20 standard amino acids have side chains that contain a variety of chemical groups—aliphatic, hydroxyl, thiol, sweet, and acidic (Uy and Wold 1977). This gives proteins a fairly different collection of chemical and physical activities for folding, catalysis, and commerce. But this color box isn't complete. For illustration, natural

amino acids don't retain azide or alkyne groups, which are critical in bio-orthogonal chemistry, nor do they include photo-cross-linkable groups demanded in spatiotemporal control of protein relations (Mehl et al. 2003; Furter 1998). In addition, canonical amino acids give many avenues for the preface of posttranslational variations like phosphorylation, glycosylation, or methylation in a point-specific and dependable way (Uy and Wold 1977; Agris 2004). The inability to include nonstandard functionalities restricts the conflation of chemically programmable proteins, biosensors, and biocatalysts with designed functions (Hao et al. 2002).

In order to surpass these biochemical constraints, approaches toward genetic code expansion have been accepted to add new structural blocks into the proteome and give it functional capability far beyond the canonical set (Polycarpo et al. 2004).

---

## Need and Strategies for Genetic Code Expansion

GCE technologies help to introduce *ncAAs*, which have been established and used in various fields of study (Switzer et al. 2023). The standard genetic code is confined to 20 canonical amino acids, thereby limiting the chemical and functional diversity of proteins that can be synthesized by organisms naturally. This major limitation poses a significant impact on various biochemical studies and synthetic biology applications. Thus, in order to overcome such limitations, GCE strategies including stop codon suppression, orthogonal tRNA, aminoacyl-tRNA synthetase (aaRS) pairs, and sense codon reassignment have been developed (Srinivasan et al. 2002). One of the important aspects of GCE in protein engineering includes point-specific protein labeling with chemical examinations, which is possible by incorporating fluorescent markers or crosslinking reagents at specific points in a protein sequence. In the field of synthetic biology, *ncAAs* have been employed to diversify biosynthetic pathways for generating new natural products as well as medicine-like composites (Chen et al. 2023). Furthermore, GCE provides substantial solutions to the biocontainment problem. This can be achieved by designing organisms to verify the presence of synthetic amino acids for successful protein function. Scientists can induce synthetic auxotrophs that cannot live outside of contained laboratory surroundings (Rovner et al. 2015). In medicine development, GCE offers a powerful approach to designing next-generation protein biologics with reduced immunogenicity and enhanced pharmacokinetic properties. Furthermore, in antibody-medicine conjugates (*ADCs*), objectification of *ncAAs* in a defined point-specific manner allows for predefined conjugation spots for cytotoxic loads. Ultimately, GCE not only improves the chemical and functional diversity of proteins beyond the limitations of the natural genetic code but also has a significant impact in novel therapeutics, the design of synthetic biological systems, and particularly in providing unique approaches for studying posttranslational modifications (PTMs) of proteins, contributing to modulation of stability, activity, and interaction of proteins (Peng et al. 2023).

The foundational principle of GCE is the incorporation of noncanonical amino acids into proteins by reprogramming the translational machinery. This requires overcoming two central challenges: first, to expand the codon capacity of the genetic

code and, second, to develop molecular tools that can selectively recognize and incorporate *ncAAs* with high fidelity and efficiency (Kryukov et al. 2003).

## Orthogonal tRNA and Aminoacyl-tRNA Synthetase (aaRS) Pairs

The central medium that makes genetic code expansion (GCE) possible is the application of orthogonal tRNA and aminoacyl-tRNA synthetase (aaRS) dyads. In nature, every tRNA is charged with its cognate amino acid by an extremely specific aaRS. This prevents the incorrect pairing of codons with amino acids during restatement (Chen et al. 2023). Orthogonal tRNA/aaRS dyads are designed so that they don't interact with the host cell's endogenous ministry (Wang et al. 2024).

These orthogonal dyads are generally attained from phylogenetically distant organisms. The most salient illustration is the tyrosyl-tRNA synthetase and tRNA brace of *Methanocaldococcus jannaschii* (Switzer et al. 2023). The brace occurs orthogonally in *Escherichia coli* and has been made to incorporate an expansive range of *ncAAs*, including photoactivatable, redox-active, and clickable remainders (Johansson et al. 2005). The synthetase undergoes directed elaboration to fit its list of funds into the target *ncAA* while retaining orthogonality.

Yet another veritably effective system comes from *Methanosarcina barkeri*, which utilizes a 22nd amino acid of natural origin, pyrrolysine, and its cognate *tRNAPyl* and *PylRS* (Polycarpo et al. 2004). This system has been reconfigured to feature numerous other *ncAAs* because of the rather flexible active point of *PylRS*, rendering it one of the most general platforms for GCE in both prokaryotic and eukaryotic cells (Kryukov et al. 2003).

These systems may be introduced into host organisms either via plasmids or by genome integration for stable expression. The effectiveness of objectification of *ncAA* is a function of colorful parameters such as the attention of the *ncAA*, situations of expression of the tRNA/aaRS brace, and competition with the endogenous termination or sense-rendering systems (Obata and Shiraiwa 2005).

## Stop Codon Suppression

A common system of genetic code expansion is the repression of stop codons, especially using the amber codon (*UAG*). This system entails the expression of an orthogonal tRNA that binds *UAG* and is loaded with the intended *ncAA* by its connate synthetase. During restatement, the ribosome adds the *ncAA* in place of the *UAG* codon, suppressing the termination of restatement (Fu et al. 2002).

The preferred amber codon is the least employed stop codon in most organisms, including *E. coli*, lowering the probability of global restatement hindrance. Also, its low frequency increases the genome-wide reassignment of *UAG* to *ncAAs* feasibility (Peng et al. 2023). For example, Church and associates synthesized a genomically recoded *E. coli* strain where all the *UAG* stop codons were substituted by synonymous *UAA* codons, and the release factor RF1 was removed. This resolved

competition from the native termination ministry and permitted the effective objectification of *ncAA* at reassigned *UAG* locales (Kryukov et al. 2003).

Despite its efficacy, amber repression has its limitations. On occasion, it can cause read-through at natural stop spots if repression is too effective, leading to the production of mutant proteins. Optimizing between repression efficacy and translational dedication remains a critical challenge (Johansson et al. 2005).

## Sense Codon Reassignment

One of the advanced styles of GCE includes sense codon reassignment to non-canonical amino acids. As sense codons are constantly set up in the genome, this procedure would bear whole-genome recoding to remove the original use of the codon of interest (Peng et al. 2023). One of the first ways in this direction was the creation of the *rE.coli-57* strain, where seven codons (all circumstances of the rare arginine codon *AGG* included) were substituted with synonymous codons throughout the genome. The released codons were later reassigned to *ncAAs* with the help of a new orthogonal restatement ministry (Peng et al. 2023).

Sense codon reassignment provides the pledge of garbling several unique *ncAAs* in one protein. But it's faced with dispiriting specialized hurdles, such as taking large-scale and high-dedication genome editing and the eventuality to destabilize native gene regulation and expression situations (Srinivasan et al. 2002).

Also, decrypting sense codons has to be achieved with veritable high delicacy to help prevent mistranslation or misincorporation. Progress in CRISPR-Cas9 systems, recombineering, and synthetic genomics has formerly started to make similar attempts more manageable, particularly in simplified or reduced genomes (Wang et al. 2024).

## Quadruplet Codon Expansion

Another promising line of pursuing the improvement of rendering capacity in organisms is the creation of quadruplet codons, where the genetic code is extended from 64 to 256 codons. The tRNAs are designed with larger anticodon circles that read four-base codons, and ribosomes are finagled to be tolerant of the new decoding figure (Obata and Shiraiwa 2005). Early work by *Schultz* and associates showed the objectification of *ncAAs* at quadruplet codons in *E. coli*, and posterior work has optimized the effectiveness of this system (Obata and Shiraiwa 2005). For example, the employment of orthogonal ribosomes—ribosomes that will preferentially restate finagled mRNAs can sequester the quadruplet decoding outfit from natural restatement, dwindling toxin, and perfecting particularity (Chen et al. 2023).

Although this system permits the contemporaneous use of several *ncAAs*, it's less effective than trinity-grounded systems because of the kinetic and structural difficulties essential in decrypting four bases rather than three. In addition, a demand for

major reengineering of ribosomal RNA and restatement factors restricts its current operation to heavily finagled strains (Wang et al. 2024). Thus, quadruplet expansion is a strong approach to synthetic biology, particularly when blended with orthogonal systems and recoded genomes. With ongoing ribosome enhancement, the effectiveness and mileage of this system are likely to increase.

---

## Incorporation of Noncanonical Amino Acids

### Chemical Diversity and Functional Classes

Noncanonical amino acids (*ncAAs*) bring unknown functional diversity beyond the natural set of 20 amino acids. These *ncAAs* add functional groups like azides, alkynes, ketones, and photo-crosslinkers to proteins, which are used for point-specific revision and new bioactivities (Chen et al. 2023). Azide- and alkyne-containing *ncAAs* are particularly useful in bio-orthogonal click chemistry, where precise posttranslational revision and labeling can be achieved without perturbing endogenous natural processes. Photoreactive *ncAAs* similar to benzophenone or diazirine are suitable to trap flash protein-protein relations by covalent bond formation upon light activation, enabling structural and interatomic studies. Likewise, posttranslational mimic *ncAAs* similar to phosphoserine, acetyllysine, or methylarginine are critical reagents for assaying intricate cellular signaling and epigenetic regulation pathways through mimicking native variations.

In addition to this, the essence-binding *ncAAs* with, for illustration, bipyridyl or thiol-functionalized side chains are employed in the design of artificial metalloenzymes to expand protein catalytic function to redox responses or essence collaboration chemistry not present in nature (Wang et al. 2024). Fluorinated *ncAAs* enhance the stability of proteins, are used to repel proteolytic fragmentation, DNA encoding, and offer better spectroscopic features for structural biology operations (Obata and Shiraiwa 2005). Redox-active remainders, similar as unnatural tyrosine or tryptophan analogs, have been incorporated into electron transfer proteins to modify their exertion or to serve as redox detectors (Cusack 1997). This functional versatility innately broadens the natural, structural, and catalytic capability of proteins and provides the base for a great deal of the progress in contemporary protein engineering and synthetic biology (Min et al. 2003).

### Genetic Engineering Tools for *ncAA* Incorporation

The effective addition of noncanonical amino acids in proteins is contingent upon a strong set of inheritable engineering tools that are able to support orthogonal translational factors. Orthogonal tRNA and aminoacyl-tRNA synthetase (aaRS) dyads that do not cross-react with the endogenous translational machinery of the host organism form the foundation of this process (Chen et al. 2023). These

orthogonal dyads are generally deduced from archaea or other phylogenetically remote organisms such as *Methanosarcina barkeri*, whose cognate tRNA and pyrrolysyl-tRNA synthetase have been engineered to have high specificity in binding a wide variety of synthetic amino acids (Polycarpo et al. 2004).

The orthogonal tRNA/aaRS genes are generally transduced into host cells in plasmid vectors. The vectors generally have inducible promoters, such as T7 or arabinose-inducible systems, to enable temporal control of gene expression (Wang et al. 2024). Codon optimization of the synthetase gene and careful engineering of the ribosome binding sites optimize the translation efficiency and fidelity further (Budisa 2025). In other cases, orthogonal elements are genomically incorporated to produce stable expression systems and exclude plasmid burden. Such integration is especially beneficial for mammalian cell-based long-term expression or synthetic bioproduction on a large scale (Tang et al. 2022).

More recently, orthogonal ribosomes that are specifically engineered to recognize orthogonal mRNA leader sequences or quadruplet codons have been constructed to maximize the fidelity of *ncAA* incorporation and reduce interference with native translational termination (Enniful et al. 2024). Synthetic ribosomes can operate alongside wild-type ribosomes for orthogonal translation of engineered proteins with minimal disruption. With advances in genome engineering tools like the CRISPR-Cas systems and synthetic recoding technologies, these approaches enhance the scope and precision of GCE technologies significantly (Peng et al. 2023).

### **Advantages of Noncanonical Amino Acids (*ncAAs*)**

One of the potent contributions of GCE lies in its ability to incorporate noncanonical amino acids (*ncAAs*), which is a complex challenge that drives groundbreaking innovation and opens possibilities for establishing an orthogonal central dogma. A major benefit of using noncanonical amino acids (*ncAAs*) is their significant contribution to recent developments in genetic code engineering and expansion. It also highlights efforts in metabolic, genomic, and strain engineering to improve genetic code redesign in the context of orthogonal translation (Budisa 2025). The key advantage of phenylalanine derivatives is to enhance the enzyme (*LmrR*) catalytic efficiency through site-specific incorporation (Wang et al. 2024). Engineered bacteria modified with *ncAAs* have the potential to achieve a highly selective catalytic synthesis of specific products (Tang et al. 2022). Modified *ncAAs* provide a unique function that offers higher control over the immobilization reaction. Also, the introduction of *ncAAs* can be genetically controlled to minimize any disruption of protein function. Especially in proteins, *ncAAs* enhance their proteolytic stability, potency, and spectrum of action (Enniful et al. 2024). Furthermore, *ncAAs* enhance GCE by enabling precise control over protein structure and function, allowing the incorporation of unique physical or chemical properties into the proteome of living cells (Tang et al. 2022). In addition, *ncAAs* synthesis for an efficient, sustainable production and growth of the valuable *ncAAs* collection (Switzer et al. 2023).

## Applications of Genetic Code Expansion (GCE)


There are several applications of GCE in various fields of study that include protein engineering and design, molecular biology, biochemistry, drug discovery and development, medicine and therapeutics, synthetic biology, chemical biology, virology and vaccine design, neuroscience, microbiology, and industrial and environmental biotechnology (Fig. 11.1). The future of codon expansion lies in the construction of universal, highly effective orthogonal restatement systems that can operate across multiple species. Directed elaboration, deep mutational scanning, and machine literacy are anticipated to speed up the identification and optimization of aaRS variants with expanded substrate reaches (Peng et al. 2023).

Combining GCE with CRISPR-intermediated gene regulation, optogenetics, and synthetic circuit design will grease dynamic control of protein function within living systems, allowing for the design of responsive or programmable cellular machines. Extending the inheritable ABC indeed further, by adding unnatural base dyads, has the implicit to opens up more rendering capability (Miranda et al. 2006). This has the implicit to enable contemporaneous objectification of several different *ncAAs*, revolutionizing our capability to wangle and manipulate natural systems. Remedial operations in tissue engineering, gene therapy, and diagnostics will all gain from GCE-proteins with bettered remedial functionality, targeted delivery, and declination biographies (Rovner et al. 2015).

In addition, semisynthetic organisms with extended canons can transfigure sustainable product systems, biosensors, and new families of biomaterials. As the technology advances, ethical and nonsupervisory paradigms will also have to advance in order to

**Fig. 11.1** Applications of genetic code expansion (GCE) in various field of studies





**Fig. 11.2** Applications of GCE in protein engineering and synthetic and systems biology

address safety, availability, and environmental impacts. Thus, genetic code expansion is a revolutionary invention in molecular biology that holds the eventuality for precise manipulation of protein structure and function (Almhjell et al. 2018). Although there are challenges, sustained invention is anticipated to push the limits of what can be achieved in life sciences and biotechnology. Although GCE plays a vital role across various fields of study, the present study primarily focuses on exploring its applications in protein engineering, as well as synthetic and systems biology (Fig. 11.2).

## Applications of GCE in Protein Engineering

### Site-Specific Labeling and Fluorescent Probes

One of the most important applications of GCE is point-specific protein labeling with chemical examinations. Using this fashion, it becomes possible to introduce fluorescent markers, affinity handles, or crosslinking reagents at specific points in a protein sequence. Labeling proteins with bio-orthogonal groups like azides or alkynes enables their specific coupling with fluorophores or other examinations using click chemistry, similar that protein dynamics within living cells can be imaged and covered in real time (Enniful et al. 2024). This system is especially strong with sophisticated luminescence imaging modalities, such as Forster resonance energy transfer (FRET), where distance-dependent energy transfer among donor and acceptor fluorophores is employed to probe protein conformational changes, binding processes, and relations (Santos et al. 2004).

In addition, GCE enables the application of photo-switchable or environmentally sensitive colorings, which are essential for super-resolution styles such as photo-activated localization microscopy (PALM) and stochastic optical reconstruction

microscopy (STORM). These tools have yielded unknown information on the nanoscale structure of protein complexes and their spatiotemporal dynamics in cells (Miranda et al. 2006).

### **Enzyme Engineering and Catalytic Optimization**

Enlarging the genetic code to encompass *ncAAs* inside enzyme active sites presents an effective strategy for customizing enzyme function. By precisely situating designed synthetic amino acids enjoying distinctive electronic or steric features, scientists can ameliorate substrate particularity, boost catalytic development, or produce whole new catalytic conditioning (Tang et al. 2022). For illustration, fluorinated tyrosine mimetics have been integrated into oxidoreductases, performing in modified redox capabilities and enhanced catalytic proficiency in redox responses (Johansson et al. 2005).

Enzymes can also be stabilized by substituting labile residues with *ncAAs* that give resistance to heat, pH, or proteolytic degradation. Synthetic remainders are also employed in some cases to develop enzyme switches or allosteric modulators that respond to external stimulants, therefore producing commutable biocatalysts (Almhjell et al. 2018). Similar differences play a pivotal part in the development of enzymes for artificial operations, synthetic metabolic pathways, and biomedical functions where native enzymes do not serve immaculately (Enniful et al. 2024).

### **Protein Therapeutics and Antibodies**

In medicine development, genetic code expansion makes possible the design of alternate-generation protein biologics with better pharmacokinetic performance and lower immunogenicity (Hao et al. 2002). The name illustration is in the area of antibody-medicine conjugates (*ADCs*), where objectification of *ncAAs* in a defined point-specific manner allows for predefined conjugation spots for cytotoxic loads. This unity results in further favorable medicine-to-antibody rates, improved remedial efficacy, and reduced off-target toxin in comparison to conventional arbitrary conjugation strategies (Agris 2004).

Outside *ADCs*, remedial proteins can be designed with *ncAAs* to enhance stability, prolong half-life, or permit targeted delivery. PEGylation handles, for example, allow polyethylene glycol to be attached to remedial enzymes, making them more stable and having longer rotation times (Enniful et al. 2024). Likewise, GCE is under investigation to produce commutable remedial proteins that only come active in defined upon exposure to complaint biomarkers, creating new opportunities in precision drug (Almhjell et al. 2018).

## **Applications in Synthetic and Systems Biology**

### **Biosynthetic Pathways for Novel Compounds**

The *ncAAs* have also been employed in synthetic biology to diversify and ameliorate biosynthetic pathways for generating new natural products, as well as medicine, such as composites. By introducing *ncAAs* into the active or nonsupervisory corridor of

enzymes for secondary metabolism, scientists can control product biographies and produce analogs with enhanced bioactivity. For example, designed polyketide synthases and non-ribosomal peptide synthetases with *ncAA* adequacy have redounded in the generation of new antibiotics and anticancer composites (Blight et al. 2004). Similar differences also make it possible to design orthogonal biosynthetic modules that can serve singly in intricate cellular climates, allowing for the production of multiple products with no cross talk. Similar approaches have tremendous eventuality for large-scale biosynthesis of intricate moles that are else prohibitively expensive or grueling to pierce via chemical conflation (Heckman et al. 1980).

### **Containment and Biocontainment Strategies**

Genetic codon expansion also offers a neat result to the biocontainment problem. By designing organisms to calculate on the presence of synthetic amino acids for successful protein function, scientists can induce synthetic auxotrophs that cannot live outside of contained laboratory surroundings (Miranda et al. 2006). This reliance serves as a natural safety cinch, minimizing the possibility of environmental release and vertical gene transfer. Similar bio-contained organisms have been suggested for use in environmental biosensing, bioremediation, and remedial microbiota engineering. Their incapability to replicate without external supplementation of *ncAAs* guarantees ecological safety and overcomes nonsupervisory issues related to the employment of genetically modified organisms (GMOs) in open surroundings (Hou et al. 2025).

### **Semisynthetic Organism Design**

The development of fully recoded genomes and orthogonal restatement systems has redounded in the generation of semisynthetic organisms with extended inheritable canons. These semisynthetic organisms, for illustration, recoded *Escherichia coli* or *Mycoplasma mycoides* strains, have been designed to carry further codons to grease the stable and effective integration of multiple *ncAAs* into proteins (Peng et al. 2023). These semisynthetic organisms are protean platforms for generating novel developer proteins with fully new structural and functional activities. Operations of these lattice organisms reach into biotechnology, medicinal, and accoutrements science to manufacture proteins of increased function, design biosensors with specific responsiveness, and synthesize polymers or biomaterials with new activities.

---

## **Challenges and Limitations**

### **Efficiency and Fidelity of *ncAA* Incorporation**

In the future of remarkable advances, the efficacy of *ncAA* objectification is still a significant limiting factor, especially in advanced eukaryotic systems. Competition with natural termination of restatement and low situations of expression of orthogonal factors can lead to poor yields or failure of objectification. Misincorporation of natural amino acids or readthrough of native stop codons can beget miscellaneous

protein products. Optimization of tRNA situations, aaRS particularity, and mRNA environment is continually being developed to enhance the dedication and potency of *ncAA* objectification (Srinivasan et al. 2002).

### **Cellular Toxins and Metabolic Burden**

The objectification of synthetic amino acids and designed translational ministry has the implicit to induce metabolic burden on host cells, impacting growth, viability, and protein folding. Certain *ncAAs* are cytotoxic or inefficiently imported, making intracellular vacuoles low (Polycarpo et al. 2004). Orthogonal element over-expression can also interfere with native processes or beget ribosomal stalling. These issues need to be overcome through scrupulous strain engineering, application of minimum synthetic media, and objectification of stress relief styles that would ensure compatibility with high-output and artificial systems.

### **Codon Operations and Genome Recoding Complexity**

Recoding codons for objectification of *ncAA* is generally demanding in terms of genome editing to remove all native cases of the target codon, especially from critical genes. The approach is time-consuming and technologically grueling, involving several rounds of CRISPR editing, recombineering, or de novo genome construction. Likewise, redundancy and environment reliance of codon operation limit selection of applicable locales for *ncAA* objectification, particularly where multiple synthetic remainders are sought (Agris 2004).

---

## **Conclusion**

Genetic code expansion (GCE) is a revolutionary platform in molecular biology, protein design, and synthetic biology that allows for the point-specific preface of noncanonical amino acids (*ncAAs*) with a wide variety of chemical functions. This technology efficiently surpasses the natural restriction of the 20 canonical amino acids, allowing experimenters to construct proteins with new activities, increased stability, and better remedial values. Using orthogonal tRNA/aminoacyl-tRNA synthetase dyads, finagled ribosomes, and recoded genomes, the genetic code has been successfully expanded to allow the expression of proteins that contain synthetic remainders at specific positions. This achievement has created new borders in both introductory exploration and applied biotechnology. The preface of *ncAAs* has converted protein labeling, structure studies, and enzyme engineering. Point-specific labeling of fluorophores and other examinations makes it possible to fantasize protein relations, conformational dynamics, and cellular localization in real-time. Catalytic elevation using designed residue chemistry has eased the design of enzymes with increased substrate particularity, reactivity, and artificial robustness.

In rectifiers, *ncAAs* are central to the design of coming-generation biologics, including antibody-medicine conjugates, half-life-extended therapeutic proteins, and commutable molecular systems responding to physiological signals. In synthetic and systems biology, *ncAAs* enable the assembly of orthogonal biosynthetic pathways, metabolic circuit engineering, and the engineering of bio-contained organisms that cannot thrive outside of well-defined surroundings. The manufacture of new antibiotics, biosensors, and polymeric accoutrements is increasingly being pushed by *ncAA*-intermediated biotechnologies. Contemporaneously, genome-wide codon reassignment and the generation of semisynthetic organisms present important platforms for future operations with multiplexed objectification of colorful chemical functionalities. Nevertheless, the area is not free from challenges. Problems like low objectification effectiveness, misincorporation, synthetic element toxin, and complexity of genome recoding still represent major hurdles to mass relinquishment. Improvements in ribosome engineering, directed elaboration, and systems-position strain optimization are necessary to transgress these limitations.

In the future, coupling GCE with new technologies like CRISPR-intermediated gene control, optogenetics, and machine literacy-grounded conflation of enzymes promises to enable accurate natural programming and regulation of synthetic circuits. As developments do, biosafety regulations and ethical considerations must adapt to maintain responsible invention and operation. Basically, GCE is reshaping the borders of protein wisdom by allowing the rational design of unprecedentedly able biomolecules. It has huge implicit to shape the future of biotechnology, drugs, and synthetic life and represents an abecedarian transition in our capability for manipulating and negotiating natural systems.

---

## References

- Agris PF (2004) Decoding the genome: a modified view. *Nucleic Acids Res* 32(1):223–238
- Almhjell PJ, Boville CE, Arnold FH (2018) Engineering enzymes for noncanonical amino acid synthesis. *Chem Soc Rev* 47(24):8980–8997
- Blight SK, Larue RC, Mahapatra A, Longstaff DG, Chang E, Zhao G, Kang PT, Green-Church KB, Chan MK, Krzycki JA (2004) Direct charging of tRNACUA with pyrrolysine in vitro and in vivo. *Nature* 431(7006):333–335
- Budisa N (2025) Introduction: “noncanonical amino acids”. *Chem Rev* 125(4):1659–1662
- Chen L, Xin X, Zhang Y, Li S, Zhao X, Li S, Xu Z (2023) Advances in biosynthesis of non-canonical amino acids (ncAAs) and the methods of ncAAs incorporation into proteins. *Molecules* 28(18):6745
- Crick FHC (1966) Codon–anticodon pairing: the wobble hypothesis. *J Mol Biol* 19:548–555
- Crick FHC (1968) The origin of the genetic code. *J Mol Biol* 38:367–337
- Cusack S (1997) Aminoacyl-tRNA synthetases. *Curr Opin Struct Biol* 7(6):881–889
- Enniful GN, Kuppusamy R, Tiburu EK, Kumar N, Willcox MDP (2024) Non-canonical amino acid bioincorporation into antimicrobial peptides and its challenges?. *J Pept Sci* 30(6):e3560
- Fu LH, Wang XF, Eyal Y, She YM, Donald LJ, Standing KG, Ben-Hayyim G (2002) A selenoprotein in the plant kingdom: mass spectrometry confirms that an opal codon (UGA) encodes selenocysteine in *Chlamydomonas reinhardtii* glutathione peroxidase. *J Biol Chem* 277(29):25983–25991
- Furter R (1998) Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in *Escherichia coli*. *Protein Sci* 7:419–426

- Hao B, Gong W, Ferguson TK, James CM, Krzycki JA, Chan MK (2002) A new UAG-encoded residue in the structure of a methanogen methyltransferase. *Science* 296(5572):1462–1466
- Heckman JE, Sarnoff J, Alzner-DeWeerd B, Yin S, RajBhandary UL (1980) Novel features in the genetic code and codon reading patterns in *Neurospora crassa* mitochondria based on sequences of six mitochondrial tRNAs. *Proc Natl Acad Sci* 77(6):3159–3163
- Hou Z, Tuo J, Ma X, Huo Y-X (2025) Recent advances in biosynthesis of non-canonical amino acids and their potentials in strain engineering. *Results Eng* 25:103641
- Johansson L, Gafvelin G, Arnér ES (2005) Selenocysteine in proteins—properties and biotechnological use. *Biochim Biophys Acta Gen Subj* 1726(1):1–13
- Kisselev L, Ehrenberg M, Frolova L (2003) Termination of translation: interplay of mRNA, rRNAs and release factors? *EMBO J* 22:175–182
- Knight RD, Freeland SJ, Landweber LF (2001) Rewiring the keyboard: evolvability of the genetic code. *Nat Rev Genet* 2:49–58
- Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigó R, Gladyshev VN (2003) Characterization of mammalian selenoproteomes. *Science* 300(5624):1439–1443
- Mehl RA, Anderson JC, Santoro SW, Wang L, Martin AB, King DS, Horn DM, Schultz PG (2003) Generation of a bacterium with a 21 amino acid genetic code. *J Am Chem Soc* 125(4):935–939
- Min B, Kitabatake M, Polycarpo C, Pelaschier J, Racznik G, Ruan B, Kobayashi H, Namgoong S, Söll D (2003) Protein synthesis in *Escherichia coli* with mischarged tRNA. *J Bacteriol* 185(12):3524–3526
- Miranda I, Silva R, Santos MA (2006) Evolution of the genetic code in yeasts. *Yeast* 23:203–213
- Obata T, Shiraiwa Y (2005) A novel eukaryotic selenoprotein in the haptophyte alga *Emiliania huxleyi*. *J Biol Chem* 280:18462–18468
- Osawa S, Jukes TH, Watanabe K, Muto A (1992) Recent evidence for evolution of the genetic code. *Microbiol Rev* 56:229–264
- Peng T, Das T, Ding K, Hang HC (2023) Functional analysis of protein post-translational modifications using genetic codon expansion. *Protein Sci* 32(4):p.e4618
- Polycarpo C, Ambrogelly A, Bérubé A, Winbush SM, McCloskey JA, Crain PF, Wood JL, Söll D (2004) An aminoacyl-tRNA synthetase that specifically activates pyrrolysine. *Proc Natl Acad Sci USA* 101:12450–12454
- Rayman MP (2000) The importance of selenium to human health. *Lancet* 356:233–224
- Rovner AJ, Haimovich AD, Katz SR, Li Z, Grome MW, Gassaway BM, Amiram M, Patel JR, Gallagher RR, Rinehart J, Isaacs FJ (2015) Recoded organisms engineered to depend on synthetic amino acids. *Nature* 518(7537):89–93
- Santos MA, Moura G, Massey SE, Tuite MF (2004) Driving change: the evolution of alternative genetic codes. *Trends Genet* 20:95–102
- Srinivasan G, James CM, Krzycki JA (2002) Pyrrolysine encoded by UAG in archaea: charging of a UAG-decoding specialized tRNA. *Science* 296:1459–1462
- Switzer HJ, Howard CA, Halonski JF, Peairs EM, Smith N, Zamecnik MP, Verma S, Young DD (2023) Employing non-canonical amino acids towards the immobilization of a hyperthermophilic enzyme to increase protein stability. *RSC Adv* 13(13):8496–8501
- Tang H, Zhang P, Luo X (2022) Recent technologies for genetic code expansion and their implications on synthetic biology applications. *J Mol Biol* 434(8):167382
- Uy R, Wold F (1977) Posttranslational covalent modification of proteins. *Science* 198:890–896
- Wang L, Zhang M, Teng H, Wang Z, Wang S, Li P, Wu J, Yang L, Xu G (2024) Rationally introducing non-canonical amino acids to enhance catalytic activity of LmrR for Henry reaction. *Bioresour Bioprocess* 11(1):26